Cetuximab [205923-56-4]
Referencia T9905-2mg
embalaje : 2mg
Marca : TargetMol
Cetuximab
Contact us for more batch information
Concentration:5.0 mg/mL
Purity:100.00%
Resource Download
COA
Cetuximab
Catalog No. T9905Cas No. 205923-56-4
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. Pack Size | |
---|---|
1 mg | |
2 mg | |
5 mg | |
10 mg | |
25 mg | |
50 mg | |
100 mg |
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
Description | Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis. |
In vitro | METHODS: Human squamous cell carcinoma (SCC) cells SCC-13Y, SCC-38, SCC-1, and SCC-11B were treated with Cetuximab (30 nM) for 8 days, and cell numbers were measured using a hemacytometer. RESULTS: Cetuximab inhibited cell proliferation of SCC cells in a time-dependent manner. Cetuximab inhibited the growth of SCC cell lines in a time-dependent manner, ranging from 20%-75% compared to untreated controls. [1] METHODS: EGFR mutant cells PC-9 and EGFR wild-type cells PC-14, A549 were treated with Cetuximab (10-100 µg/mL) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: EGFR phosphorylation was strongly expressed in PC-9 and continued to be strongly expressed during Cetuximab treatment.In PC-14 and A549 cells, although the increase in EGFR phosphorylation was reduced by the addition of Cetuximab, phosphorylation was not completely inhibited at the highest concentration. [2] |
In vivo | METHODS: To assay antitumor activity in vivo, Cetuximab (1 mg/injection) was administered intraperitoneally to BALB/c (nu/nu) mice harboring HNSCC tumors UT-SCC-2 or UT-SCC-14 on the 10th, 13th, and 16th days after tumor cell injection. RESULTS: Cetuximab treatment reduced tumor growth in HNSCC xenografts and increased local oxygen partial pressure in tumors. [3] METHODS: To study in vivo antitumor activity, Cetuximab (0.25-1 mg/mouse) was administered intraperitoneally to nude mice bearing xenograft tumors every three days for a minimum of five injections. RESULTS: Treatment with Cetuximab alone effectively delayed the growth of GEO and L2987 tumors for at least 10 days. Borderline activity was observed in A549 and WiDr xenografts. However, Cetuximab did not show any significant anti-tumor activity in HT29, HCT116, LOVO, Colo205, LX-1, HCC70 and N87 models. [4] |
Alias | Cetuximab (anti-EGFR), C225 |
Molecular Weight | 152 kDa |
Formula | C107H179N35O36S7 |
Cas No. | 205923-56-4 |
Storage | store at low temperature store at -20°C |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
InhibitorEpidermal growth factor receptorErbB-1inhibitEGFRCetuximabC-225C 225anti-EGFRHER1